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Background: Immune thrombocytopenia purpura (ITP) is an autoimmune disorder of bleeding which 
is defined as having thrombocytopenia (platelet count below 100.000/µL). Most ITP cases in children 
are acute and recent various guidelines have established a wait-and-see protocol as management for 
children with ITP since it is assumed to be temporary and will most likely to resolve spontaneously. 
Objectives: For this case report, a case of primary ITP in a child will be discussed. In the following 
discussion section, several ITP consensus guidelines will be discerned and compared to see which is 
the more appropriate guideline to adhere in managing a newly diagnosed ITP case in children. The 
case report is used as a ‘trigger’ to dissect the core treatment suggestions described in the inspected 
consensus guidelines. Case Illustration: A 6-years-old female child presents to a hospital with a chief 
complaint of having red spots in her arms and legs since a day ago. The red spots she complained was 
the first time to be experienced. She had no prior fever, (bloody) diarrhea, nausea, and vomiting. 
Physical examination showed no remarkable abnormalities other than numerous petechiae in the 
upper and lower extremities. Discussion: The patient in this case was finally admitted and treated in 
the hospital as an inpatient with corticosteroid, antibiotics, and platelet concentrates despite the 
current guidelines that generally advocate against these treatments. This case report may give an 
insight regarding the factors needed to be considered before treating a child with newly diagnosed 
ITP. Conclusion: The Joint Working Group (JWG) consensus seems to be the most comprehensive 
guideline in treatment of newly diagnosed ITP in children, compared to the American Society of 
Hematology (ASH) and International Consensus Report guideline.  





Latar Belakang: Immune trombositopenia purpura (ITP) merupakan sebuah penyakit perdarahan 
otoimun yang didefinisikan sebagai adanya trombositopenia (trombosit dibawah 100.000/µL). 
Mayoritas kasus ITP pada anak bersifat akut dan konsensus terkini menyarankan protokol “wait and 
see” sebagai tatalaksana untuk anak dengan ITP karena dianggap hanya sementara dan cenderung 
akan membaik secara spontan. Tujuan: Untuk laporan kasus ini, sebuah kasus ITP primer pada anak 
akan dibahas. Pada bagian diskusi, beberapa panduan terkait ITP akan diulas dan diperbandingkan 
untuk melihat panduan mana yang paling sesuai untuk mengatasi kasus baru (newly diagnosed) ITP 
pada anak. Laporan kasus ini digunakan sebagai pengantar untuk membahas intisari tatalaksana ITP 
dalam konsensus-konsensus yang dipakai. Ilustrasi Kasus: Anak perempuan berusia 6 tahun datang 
ke rumah sakit dengan keluhan utama adanya bintik-bintik merah pada kedua lengan dan tungkainya 
sejak sehari lalu. Bintik-bintik merah tersebut baru pertama kali dialami. Dia tidak menderita 
demam, diare (berdarah), nausea, dan vomitus. Pada pemeriksaan fisik, hanya ditemukan petekie-
petekie di kedua ekstremitas atas dan bawah. Pembahasan: Pasien dalam kasus ini dirawatinapkan 
dan diberi kortikosteroid, antibiotik, dan konsentrat trombosit sebagai tatalaksananya, meskipun 
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ini diharapkan memberikan wawasan terkait faktor-faktor yang penting untuk dipertimbangkan 
sebelum merawat seorang anak dengan kasus baru ITP. Kesimpulan: Konsensus Joint Working 
Group (JWG) tampaknya menjadi panduan paling komprehensif dalam tatalaksana anak dengan 
kasus baru ITP, dibanding panduan American Society of Hematology (ASH) dan International 
Consensus Report. 
Kata Kunci: hematologi, ITP, newly diagnosed, primer, trombositopenia 
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Immune thrombocytopenia purpura 
(ITP) is an autoimmune disorder of 
bleeding which is defined as having 
thrombocytopenia (platelet count below 
100.000/µL).
[1]
 In addition, ITP is also not 
associated with any other systemic 
illness.
[2]
 Three main mechanisms of the 
platelet’s deficiency are decreased 
production, immune-mediated destruction, 
and/or increased splenic phagocytosis of 
platelets.
[3]
 Clinical manifestations include 
petechiae, purpura, and/or ecchymosis, 
which usually appear in upper and lower 
extremities.
[2]
 The mucocutaneous 
bleeding symptoms can also occur, i.e., 
gums, hard palate, or nasal septum, which 
often lead to nose and/or gum 
bleedings.
[1,2] 
According to the new 
classification after 2009, the diagnosis of 
ITP can be classified into three types, i.e., 
newly diagnosed (<3 months), persistent 




In about 80% of ITP cases, the 
underlying cause(s) are usually not found, 
i.e., primary ITP; the other 20% of cases 
present the ITP as a manifestation 
secondary to coexisting disease(s).
[3]
 In 
these secondary ITP, the etiologies often 
include infections, malignancies, and some 
immunodeficiency and autoimmune 
diseases.
[4]
 Most ITP cases in children are 
of acute origin and are preceded by a viral 
illness.
[4,5]
 Recent various guidelines have 
established a wait-and-see protocol as 
management for children with ITP since it 
is assumed to be temporary and will most 
likely to resolve spontaneously.
[6-8]
 For 
this case report, a case of primary ITP in a 
child will be discussed, with the emphasis 
of considerations for medication treatment. 
 
 
A female child, 6 years old, presents 
to a hospital with a chief complaint of 
having red spots in her arms and legs since 
a day ago. She had no prior fever, (bloody) 
diarrhea, nausea, and vomiting. A nose 
bleeding was confessed by the patient but 
no gum bleeding. She felt just a slight 
decrease in appetites. History of allergy 
was denied. She reported no history of 
hospitalization. The red spots she 
complained was the first time to be 
experienced. 
On physical examination, the patient 
was stable. No abnormalities in vital signs 
were found. She was fully aware (Glasgow 
Coma Scale = 15) and had a good nutrition 
status. All the examinations were normal 
except for the upper and lower extremities, 
where numerous petechiae were found. No 
bruises were discovered. The nostrils were 
clean with no blood when checked. The 
gum and mouth were within normal 
findings. 
The patient was then diagnosed with 
suspected dengue hemorrhagic fever 
(DHF), with differential diagnosis of ITP. 
Ringer lactate (RL) infusion of 1.000 
mL/24h, routine hematology (hemoglobin, 
hematocrit, leucocyte, thrombocyte), blood 
glucose, and blood type testing were 
initially conducted. Upon completion, the 
laboratory results gave normal results 
except for thrombocyte level of just 
4.000/µL. The patient was then consulted 
to a pediatrician. The specialist decided to 
order complete hematology testing 
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indices, Westergren erythrocyte 
sedimentation rate/ESR, red blood cell 
distribution width/RDW, leucocyte 
differential count) and peripheral blood 
smear examination for further checkups. 
The diagnosis was changed into ITP and 
the patient was treated with cefotaxime, 
prednisone, and thrombocyte concentrate 
infusions. The patient was transferred to a 
high care unit for strict observations due to 
extremely low platelet level in her blood. 
The drugs were given shortly without 
waiting for complete hematology testing 
results first. The medications (cefotaxime 
and prednisone) were to be given daily, 3 
times a day at an appropriate dosage. The 
thrombocyte concentrate was also to be 
infused for 3 units a day for 2 days. 
The requested peripheral blood smear 
testing was done before the treatment 
commenced. The examination gave 
abnormal results for thrombocyte, i.e., 
lowered estimated amount and existence of 
giant thrombocytes. No platelet clumping 
was reported. The erythrocytes were 
described to be hypochromic microcytic, 
polychromatic, and mild-moderate 
anisocytosis. The leucocytes were 
otherwise normal. Meanwhile, the 
complete hematology testing was 
undertaken after the first day of treatment. 
An improved number for thrombocyte 
level was observed at 12.000/µL. All other 
parameters were still within normal limits. 
Another blood testing was conducted 
after the second day of treatment. Further 
improvement of thrombocyte level was 
seen at 91.000/µL. In response to the 
result, no additional thrombocyte infusions 
were given and the patient was kept 
monitored for another one day (third day) 
to make sure the progress is in the right 
track. The cefotaxime and prednisone were 
still continually administered. 
The next day (fourth day), the patient 
was discharged from hospital at noon 
without any symptom. Some petechiae 
were still found at the arms and legs but 
had been reduced significantly in numbers. 
There was no blood testing at the day 
before the discharge. The patient was 
given methylprednisolone tablet as take-
home medicine, taken 3 times a day for 3 
days. After 3 days passed, the patient was 
returning to hospital to visit a pediatrician 
office at the outpatient clinic to monitor 
further progress of improvement. At this 
time, the blood testing was requested as 
final confirmation to see whether the 
thrombocyte had returned to normal level. 
A thrombocyte level of 520.000/µL was 
yielded. All other parameters were again 
within normal limits. The petechiae were 
no longer seen at the moment. The patient 
was then given additional 
methylprednisolone tablets for the next 4 
days as a tapering-off medication. 
 
 
This patient was initially diagnosed 
with DHF due to the presenting 
appearance of petechiae in the patient, as 
well as the endemicity of such disease in 
the region. However, the ITP was made as 
differential because the patient was not 
reporting any fever prior to the petechiae’s 
emergence. After the discovery of isolated 
thrombocytopenia in this patient through 
first blood testing, the final diagnosis was 
changed to ITP and the dengue serology 
was not checked because there was no 
fever complained by the patient and there 
was no any hematocrit increase, 
warranting the exclusion of DHF as 
diagnosis. Although the erythrocytes 
morphology was reported to be abnormal 
in the peripheral blood smear examination, 
the hemoglobin level and red blood cell 
indices values in this patient remain 
normal. Based on the newest classification 
of ITP diagnosis, this patient is suitable to 
be classified as newly diagnosed ITP 
(from diagnosis until 3 months). On the 
case of this patient, the appearance of 
petechiae without bruises corresponds to a 
grade 1 (minor) or 2 (mild) ITP, according 
to the newest 2019 International 
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Grade 1 (minor) Minor bleeding, few petechiae (≤100 total) and/or ≤5 small bruises (≤3 cm in 
diameter), no mucosal bleeding 
Grade 2 (mild) Mild bleeding, many petechiae (>100 total) and/or >5 large bruises (>3 cm in 
diameter), no mucosal bleeding 
Grade 3 (moderate) Moderate bleeding, overt mucosal bleeding, troublesome lifestyle 
Grade 4 (severe) Severe bleeding, mucosal bleeding leading to decrease in Hb >2 g/dL or 
suspected internal haemorrhage 
 
The most recent American Society of 
Hematology (ASH) 2019 consensus 
guideline has suggested that children with 
newly diagnosed ITP who have no or 
minor bleeding should be observed only 
without the need to be given any therapy - 
even for corticosteroid - regardless of 
platelet counts.
[6]
 No additional remark or 
consideration was described. This is quite 
in contrast to the guideline issued by the 
joint working group (JWG) of some 
European hematology associations 
(Germany, Austria, Switzerland) in 2018
[8]
 
and the 2019 International Consensus 
Report on ITP,
[7]
 which offer more flexible 
approaches to manage ITP children 
without or with only mild bleeding 
symptom. Both guidelines are 
fundamentally in accordance with the ASH 
consensus, i.e., treatments are usually not 
necessarily needed for newly diagnosed 
ITP in children without or with only mild 
bleeding, even when the platelets are 
extremely low (<20-30.000/µL). However, 
the JWG consensus also emphasizes the 
need to consider other factors in deciding 
whether to start treatment or observation 
alone, especially the social factors. The 
consequences for school activities, 
patient’s preference, medication and 
(psycho)social background, and access to 
healthcare facilities are among factors that 
need to be considered when deciding the 
suitable management for newly diagnosed 
ITP children without or with only mild 
bleeding. Although the guideline 
acknowledges the very low platelet level 
status (<20-30.000/µL) as an indicator for 
risk of severe hemorrhage, it also states 
that a treatment decision based only on 
platelet count without looking at individual 
patient’s circumstances is no longer a 
standard algorithm. Should the medication 
therapy be decided to be given to the 
patient, the JWG supports the 
corticosteroid as first-line therapy to be 
given. The offer for such treatment is 
especially if the patient is afraid of 
bleeding and the wavering to give 
medication will hardly be acceptable.
[8]
 
Similar considerations are also 
described in the 2019 International 
Consensus Report on ITP. Most children 
with newly diagnosed ITP do not require 
any therapy because the platelet level will 
often restore to normal within few days.
[7] 
The consensus also encourages 
hospitalization only for children with 
grade 3 or 4 bleeding. Nonetheless, several 
cases may warrant the hospitalization and 
treatment be appropriate to be 
administered: risk of intracranial bleeding, 
anxious or worried parents due to the 
disease, far distance from the hospital.
[7]
 
There is scarcity of recent clinical trial 
comparing the efficacy of corticosteroid 
treatment versus observation alone. A 
study by Blanchette et al. in 1993 
supported the use of prednisone as initial 
therapy in children with acute and severe 
ITP.
[9]
 Similar suggestion was also put 
forward by Carcao et al. in their 1998 
study.
[10]
 Prednisone was deemed safe, 
inexpensive, and effective to increase 
platelet level after a week. However, a 
study countering the Blanchette and 
Carcao’s study finding for prednisone 
therapy was published by Buchanan and 
Holtkamp in their 1984 study of the same 
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diagnosed ITP.
[11]
 They reported no 
significant differences between the 
children treated with prednisone and 
placebo. Supporting the Buchanan and 
Holtkamp’s study, was the study by 
Dickerhoff and von Ruecker in 2000. They 
conducted a retrospective clinical trial 
study and concluded that most studied 
children were not given any therapy for 
their ITP, even when platelet count was 
<10.000/µL.
[12]
 These conflicting studies 
may be the background reason of the 2019 
ASH consensus suggesting against the use 
of corticosteroid therapy. The ASH 
consensus panelists have determined that 
the possible harms of corticosteroid use – 
even for short course – outweigh the 
unclear, controversial benefit perceived. 
On the case of the patient in this case 
report, although she had only petechiae 
without any bruise, the occurrence of 
platelet level <10.000/µL in blood testing 
result made the decision to treat with a 
corticosteroid justifiable to reduce the 
possibility of more severe bleeding that 
may happen if not assisted with the 
prednisone medication. Another 
consideration was the age of the patient 
when diagnosed and her parent’s effort to 
visit the hospital ‘only’ for some red spots 
on the patient’s arms and legs without any 
fever. At 6 years old, the child will be 
expected to be highly active which puts 
her as high risk for possible bleeding 
caused by daily activities. Further, the visit 
to hospital should be interpreted that her 
parent is already in concern with the 
unusual, petechiae symptom acquired in 
the child. The 2018 JWG guideline or 
2019 International Consensus Report 
seems to be the most suitable consensus to 
adhere when managing newly diagnosed 
ITP children without or with mild 
bleeding. These guidelines give thorough 
considerations before deciding to treat the 
patients by judging not only from the 
bleeding grade or platelet count level but 
also from the individual patient’s 
circumstances. 
Regarding the use of antibiotics, the 
JWG consensus states that such use as 
infection prophylaxis is usually not 
needed. In this case report, the patient was 
given cefotaxime as prophylactic 
antibiotic. The patient’s hospital almost 
always has many other patients to admit 
with various kinds of diseases, putting the 
hospital vulnerable to be populated with 
many infectious organisms. Although the 
ITP itself is not a bacterial-caused disease, 
the antibiotic was still administered to 
reduce the risk to contract any iatrogenic 
disease. There was no statement about the 
use of antibiotics recommendation in the 
ASH and International Consensus Report 
guideline. 
The use of thrombocyte concentrate 
infusion has been described in the JWG 
and International Consensus Report 
guideline. No such infusion is described as 
a treatment regime in the ASH guideline. 
Both JWG and the International Consensus 
Report guideline state the thrombocyte 
concentrate infusion to be used only in 
emergency situation. The International 
Consensus Report guideline suggests to 
use the infusion in case of organ- or life-
threatening bleeding to increase the 
platelet level as immediately as possible. A 
more specific suggestion is seen on the 
JWG consensus, recommending the 
platelet infusion to be given to patients 
with severe, World Health Organization 
(WHO) grade III/IV bleeding (see Table 
2). In this case report, although no major 
bleeding was occurring in the patient, the 
thrombocyte infusion was given with the 
same reason as the rationale of the 
prednisone therapy, i.e., to reduce the 
likelihood of more severe bleeding 
resulted from such an extremely low 
platelet count. Fortunately, no adverse 
reaction was seen in the patient during the 
infusion therapy. 
The infusion initiation was in 
accordance to Squire’s review article, 
which recommends to start thrombocyte 
transfusion when the level falls below 
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thrombocytopenic patients without 
complicating comorbidities (fever, prior 
infection, being treated with drugs known 
to damage the platelets).
[13]
 Similar with 
the JWG and International Consensus 
Report, Squire also emphasizes the 
infusion therapy to be individualized and 
adjusted to the current clinical situations 
faced. 
Taken together, compared to the ASH 
and the International Consensus Report 
guideline, the JWG consensus is likely to 
be more comprehensive and specific 
guideline to consider when dealing with 
newly diagnosed ITP cases in children due 
to its extensive details in every treatment 
aspect for the disease, especially for the 
patient’s preference and circumstances. 
 
 
The decision to treat a newly 
diagnosed children with ITP should be 
based not only on platelet count or 
bleeding grades, but also the individual 
patient’s circumstances. Reviewing the 
most current guidelines about the 
management of newly diagnosed ITP in 
children, the 2018 consensus published by 
the JWG or 2019 International Consensus 
Report seems to give a more relevant and 
comprehensive recommendations to 
consider in deciding the treatment regime 
compared to the 2019 ASH guideline. 
Incorporation of remarks to address 
individual patient’s circumstances in the 
treatment decision and the thrombocyte 
infusion should be written in the next, 
revised ASH guideline to make this 
guideline more appropriate and practical to 
be referred to
 
Table 2. Bleeding scales according to the WHO.
[8]
 
Bleeding grade Definition 
0 No signs of bleeding 
I Petechiae 
Small hematomas, ecchymoses (<10 cm) 
Bleeding from mucous membranes (mouth, nose) 
Epistaxis (<1 h duration, no medical intervention necessary) 
Subconjunctival hemorrhages 





Hematomas, ecchymoses (>10 cm) 
Epistaxis (>1 h duration or tamponade necessary) 
Retinal bleeding without visual impairment 
Vaginal bleeding (independent of menstruation, more than 2 bandages/day 
necessary) 
Melena, hematemesis, hemoptysis, hematuria, hematochezia 
Bleeding from puncture sites 





Bleeding from mucous membranes (mouth, nose) 
Vaginal bleeding 
Melena, hematemesis, hemoptysis, hematuria, hematochezia 
Bleeding from puncture sites 







Retinal hemorrhage with visual impairment 
CNS bleeding 
Hemorrhages in other organs with functional impairment (joints, muscles, 
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